'its just a 20:1 cbd/thc mix... you can get it online for 50 bucks a bottle today if youd like...Yes a simple 20:1 blend helps reduce seizures, but what puts cannepil above any other company with their own 20:1 combo'?
IMO, I'd say GMP puts CannEpil above other companies who simply advertise their products online for $50 a bottle! It appears from company reports that GMP certification was the green light MXC was waiting for to go ahead with sales, at the very least in Australia, for which it has been endorsed under the TGA, as indicated in their company announcement released on 11th Oct 2018:
-MXC’s Medicinal Cannabis based IMP, CannEpilTM is now available for supply in Australia under the Authorised Prescriber Scheme
-Authorisation has been granted by the TGA to specialist prescribers who are now authorised to supply CannEpilTM to patients in Australia
-Authorisation follows recent Human Research Ethics Committee endorsement from St Vincent’s Hospital Melbourne for the use of CannEpilTM in the treatment of adult patients with drug-resistant epilepsy
-Represents a major milestone for MXC, validating and confirming its seed-topharma strategy with the start of commercial supply of its first IMP offering
-The Company expects this to initially generate $1 million in annualised revenue from the initial base of approximately 100 patients
-CannEpilTM is expected to be available for supply in Australia by December 2018
MXC Price at posting:
5.4¢ Sentiment: Buy Disclosure: Held
